Abstract: SA-PO462
Progression to ESKD in Type 2 Diabetes by Histological Findings: A Retrospective Cohort Study
Session Information
- Diabetic Kidney Disease: Clinical - II
November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 702 Diabetic Kidney Disease: Clinical
Authors
- Haar, Karina, Department of Medicine, Zealand University Hospital, Roskilde, Denmark
- Persson, Frederik, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark
- Bressendorff, Iain Oshoj, Department of Nephrology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
- Hansen, Ditte, Department of Nephrology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
- Møller, Marie, Department of Nephrology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
- Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Denmark
- Borg, Rikke, Department of Medicine, Zealand University Hospital, Roskilde, Denmark
Group or Team Name
- PRIMETIME.
Background
The risk of progression to end-stage kidney disease (ESKD) varies among individuals with type 2 diabetes (T2D). This study aims to investigate if the risk of progression to ESKD differ by biopsy-proven type of kidney disease.
Methods
We conducted a retrospective cohort study including all adults with T2D in Denmark from 1996-2020 who had a kidney biopsy performed. The individuals were previously classified as having diabetic nephropathy (DN) (n=599), non-diabetic nephropathy (NDN) (n=703), mixed disease (n=165), normal histopathology (n=49), or could not be classified (NC) (n=743). Using high-quality national registry data, the cohort was described with demographic, clinical, and laboratory data and comorbidity. Stratified analysis of progression to ESKD within the type of kidney disease was performed.
Results
The cohort consisted of 68% men with mean age 64.1+11.2 years at biopsy. At the time of biopsy, the DN group had systolic blood pressure (SBP) 144±20 mmHg and a body mass index (BMI) of 30.9±6.2 kg/m2. They had a median and interquartile range [IQR] estimated glomerular filtration rate (eGFR) 39 [24.0, 59.2] ml/min/1.73m2 and median [IQR] urine albumin-creatinine ratio (UACR) 2373 [890.2, 4183.5] mg/g. The NDN group had SBP 138±21 mmHg, a BMI of 30.8±6.5 kg/m2, eGFR 29 [15.0, 58.0] ml/min/1.73m2, and UACR 766 [95.5, 2394.5] mg/g. The mixed disease group had SBP 147±21 mmHg, a BMI of 31.7±6.1 kg/m2, eGFR 25 [11.0, 48.0] ml/min/1.73m2 and UACR 1863 [583.0, 3400.0] mg/g. We found a significant difference in the rate of renal progression (p < 0.001). During a median follow-up of 12.8 years, progression to ESKD occurred in 52% with DN, 42% with NDN, 53% with mixed disease, 25% with normal histopathology, and 41% with NC. Time to ESKD from diagnosis of T2D was significantly different within the type of kidney disease (p < 0.001); 13.2 [8.0, 17.9] median [IQR] years in DN, 7.8 [4.5, 12.8] years in NDN, 13.0 [7.8, 17.3] years in mixed disease, 6.3 [1.3, 11.1] years in normal histopathology, and 9.2 [5.1, 14.6] years in NC.
Conclusion
In people with T2D, we found the highest rate of ESKD in DN and mixed disease, but with the slowest time to progression. Analyses suggest that the risk of and time until progression to ESKD differs significantly within types of biopsy-proven kidney disease.
Funding
- Private Foundation Support